Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system
Authors Al-Ahmad M, Alowayesh M, Carroll N
Received 22 October 2015
Accepted for publication 23 February 2016
Published 10 May 2016 Volume 2016:8 Pages 163—169
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Qian Ding
Peer reviewer comments 2
Editor who approved publication: Professor Giorgio Lorenzo Colombo
Mona Al-Ahmad,1 Maryam S Alowayesh,2 Norman V Carroll3
1Microbiology Department, Faculty of Medicine, 2Pharmacy Practice Department, Faculty of Pharmacy, Kuwait University, Kuwait; 3Division of Pharmacoeconomics and Health Outcomes, School of Pharmacy, Virginia Commonwealth University, VA, USA
Background: Chronic spontaneous urticaria (CSU) is a common problem worldwide. We evaluated the direct medical costs of treating patients with refractory CSU and the budget effect of omalizumab use in these patients in Kuwait.
Methods: The prevalence of CSU was estimated using the Delphi method. Medical records of patients with refractory CSU in Kuwait were reviewed. Costs were calculated from a health system perspective. One-way sensitivity analyses were conducted on the price and utilization of each cost component.
Results: Before omalizumab use, the total direct costs of treating 1,293 patients with refractory CSU were estimated to be USD 3,650,733 per year. This estimation was principally generated by outpatient visits. After omalizumab use, the cost was sensitive to price variation and estimated to be USD 15,828,612 per year. All other direct costs were reduced.
Conclusion: The economic burden of refractory CSU in Kuwait is high. Omalizumab use is costly, but its administration reduces all other direct costs.
Keywords: cost, chronic urticaria, Kuwait, omalizumab, economic, Middle East
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]